共 50 条
- [1] POTENT TUMOR-DIRECTED T CELL ACTIVATION AND IN VIVO TUMOR INHIBITION INDUCED BY A 4-1BB X 5T4 ADAPTIR™ BISPECIFIC ANTIBODYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A507 - A507Nelson, MichelleMiller, RobertNilsson, AnneliLjung, LillChunyk, AllisonMcMahan, CatherineBienvenue, DavidAskmyr, MariaHernandez-Hoyos, GabrielaFritzell, Sara
- [2] Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibodyCANCER RESEARCH, 2019, 79 (13)Dahlman, AnnaNelson, MichelleBannink, JeannetteJohnson, StarrlaWerchau, DoreenNilsson, AnneliLjung, LillBlahnik-Fagan, GabrieleBader, RobertDeronic, AdnanEllmark, PeterAskmyr, MariaHernandez-Hoyos, GabrielaMcMahan, CathyFritzell, Sara
- [3] ALG.APV-527: A 5T4 TUMOR DIRECTED BISPECIFIC APPROACH UTILIZING ADAPTIRTM TECHNOLOGY DESIGNED FOR CONDITIONAL 4-1BB T CELL/NK AGONISM AGAINST SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A831 - A831Nelson, MichelleSundstedt, Anettede Coana, Yago PicoLucas, AshlyNilsson, AnneliLjung, LillChunyk, AllisonSchultz, LenaMcMahan, CatherineGross, JaneFrizell, SaraRamos, HilarioEllmark, Peter
- [4] Claudin 18.2 X 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activationCANCER RESEARCH, 2020, 80 (16)Jiang, WenqingFang, LeiWang, ZhengyiGuo, Taylor B.Park, EunyoungSung, EunsilJung, Jaeho
- [5] The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Activation and Potent Antitumor Activity in Preclinical StudiesMOLECULAR CANCER THERAPEUTICS, 2023, 22 (01) : 89 - 101Nelson, Michelle H.Fritzell, SaraMiller, RobertWerchau, DoreenVan Citters, DanielleNilsson, AnneliMisher, LyndaLjung, LillBader, RobertDeronic, AdnanChunyk, Allison G.Schultz, LenaVaras, Laura A.Rose, NadiaHakansson, MariaGross, JaneFurebring, ChristinaPavlik, PeterSundstedt, AnetteVeitonmaki, NiinaRamos, Hilario J.Sall, AnnaDahlman, AnnaBienvenue, Davidvon Schantz, LauraMcMahan, Catherine J.Askmyr, MariaHernandez-Hoyos, GabrielaEllmark, Peter
- [6] First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable diseaseANNALS OF ONCOLOGY, 2024, 35 : S524 - S525Marron, T.Rosen, S.Orr, D.Powderly, J., IIKhaskhely, N.Bonham, L.Nelson, M.Taromino, C.Taylor, D.Kumer, J.Ellmark, P.Fritzell, S.Ambarkhane, S. V.Huebner, D.Alahmadi, A.
- [7] A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activationCANCER RESEARCH, 2020, 80 (16)Song, Moo YoungLee, Eun-JungChung, HyejinLee, YangsoonPark, Young BongJee, Min HyeokKim, KyeongBaeJu, MikyeongLee, Jun KyungChoi, Byung HyunPark, Ju YoungKim, DaeWonKim, JunhwanAhn, SujinAhn, Kyoung KyuPark, KyeongsuJung, UijungSon, WonjunEom, JaehyunKim, EunjungYeom, DonghoonAhn, JinhyungSong, DaehaeSung, ByungjeYou, Weon-kyooKim, Jong GyunOh, Se-WoongJung, Jaeho
- [8] CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activationJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)Gao, JingWang, ZhengyiJiang, WenqingZhang, YanniMeng, ZhenNiu, YanlingSheng, ZhenChen, ChanLiu, XuejunChen, XiLiu, ChanjuanJia, KerenZhang, ChengLiao, HaiyanJung, JaehoSung, EunsilChung, HyejinZhang, Jingwu Z.Zhu, Andrew X.Shen, Lin
- [9] Discovery of a novel Claudin 6 X 4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activationCANCER RESEARCH, 2022, 82 (12)Li, JianJiang, WenqingLiu, YanWang, ZhengyiChen, XiGuo, Taylor B.
- [10] A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activationANNALS OF ONCOLOGY, 2021, 32 : S607 - S608Lee, E.Chung, H.Lee, Y.Lee, E-J.Park, Y. B.Kim, Y.Park, J. Y.Ahn, S.Kim, J.Ahn, K. K.Park, K.Son, W.Yeom, D.Jung, J.Won, J.Oh, S.